Fourth of July Fireworks came a week early at the US FDA, as the agency approved a glut of novel treatments on top of a massive burst of submission and review announcements. Here's your news in brief:
With approvals for Achaogen Inc.'s Zemdri (plazomicin), GW Pharmaceuticals PLCEpidiolex (cannabidiol) and Array Biopharma Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?